Dynavax Technologies | DVAX - Cash And Equivalent



Dynavax Technologies reported $99.1M in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
AbbVie USD 5.18B 349M Mar/2025
Adma Biologics USD 90.28M 12.87M Jun/2025
Amgen USD 8.03B 782M Jun/2025
AstraZeneca USD 7.06B 1.83B Jun/2025
Biogen USD 2.76B 160.5M Jun/2025
BioMarin Pharmaceutical USD 1.21B 601.78M Jun/2025
Bristol-Myers Squibb USD 12.6B 1.72B Jun/2025
Dynavax Technologies USD 99.1M 562.24M Jun/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
Glaxosmithkline GBP 3.6B 271M Jun/2025
Merck USD 8.01B 622M Jun/2025
Neurocrine Biosciences USD 264M 69.9M Jun/2025
Novartis USD 6.66B 410M Jun/2025
Pfizer USD 1.64B 208M Jun/2025
Regeneron Pharmaceuticals USD 2B 1.09B Jun/2025
Roche Holding CHF 6.98B 2.15B Dec/2024
Sarepta Therapeutics USD 510.6M 269.73M Jun/2025
TG Therapeutics USD 278.86M 146.72M Jun/2025
Vertex Pharmaceuticals USD 6.38B 1.71B Jun/2025